ReviewJournal of reproductive immunology2014
Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia.
Review in Journal of reproductive immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03648970 (Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pravastatin to Prevent Preeclampsia and Reduce Maternal-Neonatal Mortality and Morbidity in High Risk Preeclampsia Patients
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Pooled it
- Trial
- FABP4 Downregulated by FOS Alleviates Palmitic Acid-induced Endothelial Cell Dysfunction Via Inactivating ERK/STAT-1 Signaling Pathway.Cell biochemistry and biophysics · 2025Article
- Iron-Immune Crosstalk at the Maternal-Fetal Interface: Emerging Mechanisms in the Pathogenesis of Preeclampsia.Antioxidants (Basel, Switzerland) · 2025Review
- Heme oxygenase/carbon monoxide system affects the placenta and preeclampsia.Medical gas research · 2025Review
- Secondary prevention of preeclampsia.Frontiers in cell and developmental biology · 2025Review
- Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.American journal of obstetrics and gynecology · 2023Article
- Heme Oxygenase-1 Signaling and Redox Homeostasis in Physiopathological Conditions.Biomolecules · 2021Review
- Modelling preeclampsia: a comparative analysis of the common human trophoblast cell lines.FASEB bioAdvances · 2021Article
- Heme Oxygenase Dependent Bilirubin Generation in Vascular Cells: A Role in Preventing Endothelial Dysfunction in Local Tissue Microenvironment?Frontiers in physiology · 2020Review
- Cholesterol Crystals and NLRP3 Mediated Inflammation in the Uterine Wall Decidua in Normal and Preeclamptic Pregnancies.Frontiers in immunology · 2020Article
- Developing novel in vitro methods for the risk assessment of developmental and placental toxicants in the environment.Toxicology and applied pharmacology · 2019Review
- A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy.Current hypertension reports · 2019Review
- Dyslipidemia and the role of adipose tissue in early pregnancy in the BPH/5 mouse model for preeclampsia.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Article
- Pre-eclampsia: pathogenesis, novel diagnostics and therapies.Nature reviews. Nephrology · 2019Review
- Placental Origins of Preeclampsia: Potential Therapeutic Targets.Current medical science · 2019Review
- Angiogenic factors: potential to change clinical practice in pre-eclampsia?BJOG : an international journal of obstetrics and gynaecology · 2018Review
- Trophoblast retrieval and isolation from the cervix: origins of cervical trophoblasts and their potential value for risk assessment of ongoing pregnancies.Human reproduction update · 2018Review
- Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms.PloS one · 2018Article
- Neurodevelopment at Age 10 Years of Children Born <28 Weeks With Fetal Growth Restriction.Pediatrics · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Heme oxygenase (Hmox) is an endogenous system that offers protection against placental cytotoxic damage associated with preeclampsia. The Hmox1/carbon monoxide (CO) pathway inhibits soluble Flt-1 (sFlt-1) and soluble Endoglin (sEng). More importantly, statins induce Hmox1 and suppress the release of sFlt-1 and sEng; thus, statins and Hmox1 activators are potential novel therapeutic agents for treating preeclampsia. The contribution of the Hmox system to the pathogenesis of preeclampsia has been further indicated by the incidence of preeclampsia being reduced by a third in smokers, who had reduced levels of circulating sFlt-1. Interestingly, preeclamptic women exhale less CO compared with women with healthy pregnancies. Hmox1 is reduced prior to the increase in sFlt-1 as Hmox1 mRNA expression in the trophoblast is decreased in the first trimester in women who go on to develop preeclampsia. Induction of Hmox1 or exposure to CO or bilirubin has been shown to inhibit the release of sFlt-1 and sEng in animal models of preeclampsia. The functional benefit of statins and Hmox1 induction in women with preeclampsia is valid not only because they inhibit sFlt-1 release, but also because statins and Hmox1 are associated with anti-apoptotic, anti-inflammatory, and anti-oxidant properties. The StAmP trial is the first randomized control trial (RCT) evaluating the use of pravastatin to ameliorate severe preeclampsia. This proof-of-concept study will pave the way for future global RCT, the success of which will greatly contribute to achieving the United Nations Millennium Development Goals (MDG4 and MDG5) and offering an affordable and easily accessible therapy for preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.